How to Lose More Weight on Ozempic: Effective Strategies and Insights

Last reviewed: July 2, 2026

Last updated: July 2, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The single most useful correction to this question is that Ozempic is not a weight-loss drug. According to the Ozempic prescribing information, it is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes; to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; and to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. If weight is your primary goal, the most consequential conversation you can have is with your prescriber about whether you are on the right product for that goal. Everything else — what genuinely amplifies weight change alongside a GLP-1 medication — is well studied, and it is not what most people expect.

Start With Whether You Are on the Right Product

Semaglutide is approved for weight management under a different brand and a different label, with a different set of indications and a different dosage ceiling. Someone taking Ozempic for type 2 diabetes and hoping it doubles as an obesity treatment is asking a diabetes regimen to hit a target it was not titrated against — the label states the maintenance range is determined by glycemic control needs.

This is not a technicality. It changes what your prescriber is optimizing, what your plan is willing to authorize, and what evidence base applies to you. Before adjusting anything else, it is worth asking directly: given my diagnoses, is this the product that matches my goals?

Diabetes Itself Changes the Trajectory

People with type 2 diabetes consistently lose less weight on semaglutide than people without it, and the trials quantify the gap. STEP 1 enrolled 1,961 adults without diabetes and reported a mean body weight change of −14.9% at week 68 with semaglutide 2.4 mg versus −2.4% with placebo. STEP 2, which enrolled 1,210 adults who had both overweight or obesity and type 2 diabetes, reported −9.6% at the same 68-week mark versus −3.4% with placebo.

Same molecule, same duration, roughly a third less weight change. If you have diabetes and your results look modest against what you see online, the comparison is probably unfair rather than the result disappointing. Insulin and certain other glucose-lowering medications also influence weight, which is one more reason this belongs in a conversation with the clinician managing your regimen.

Structured Behavioral Support Is Not a Footnote

The largest lever with real trial evidence behind it is the least glamorous. STEP 3, published in JAMA, enrolled 611 adults for 68 weeks with intensive behavioral therapy delivered to every participant alongside an initial low-calorie diet. At week 68, estimated mean body weight change was −16.0% with semaglutide versus −5.7% with placebo.

Two things stand out. The placebo group — receiving structured behavioral support and nothing pharmacologically active — lost more than twice what placebo groups typically lose in trials without that scaffolding. And the medication group's result was the largest across the STEP program. Structured support did not replace the drug or compete with it; it stacked. "Eat better" is advice. A defined program with accountability is an intervention, and it behaves like one in the data.

Exercise Changes What You Lose, Not Just How Much

A randomized head-to-head trial published in the New England Journal of Medicine put this question to the test directly. After an 8-week low-calorie diet in which 195 adults with obesity lost a mean of 13.1 kg, participants were randomized for one year to a moderate-to-vigorous exercise program plus placebo, to liraglutide plus usual activity, to both combined, or to placebo plus usual activity.

All three active strategies beat placebo, but the combination beat each alone in the way that matters most. Body-fat percentage fell 3.9 percentage points in the combination group — roughly twice the reduction seen with exercise alone (−1.7 points) or the medication alone (−1.9 points). Only the combination improved glycated hemoglobin, insulin sensitivity, and cardiorespiratory fitness. The scale reports one number; that number conceals whether you are losing fat or losing the lean tissue that sets your metabolic rate.

Plateaus Are Expected, and Stopping Is Not a Finish Line

Weight loss on these medications is not linear and does not continue indefinitely. Bodies defend a lower weight through hormonal and metabolic adaptation, and a plateau is the physiology working as designed rather than evidence that the medication has stopped working.

What happens after treatment is the more sobering finding. In the STEP 1 trial extension, 327 participants were followed for a year after semaglutide 2.4 mg and the lifestyle intervention were both withdrawn at week 68. Mean weight loss had been 17.3% at week 68; by week 120, participants had regained 11.6 percentage points of that, leaving a net 5.6% below baseline, and most cardiometabolic improvements had reverted toward baseline. The authors concluded that ongoing treatment is required to maintain the improvements. Obesity behaves as a chronic condition, and the plan you build should assume that.

What Does Not Count as a Strategy

Self-adjusting your regimen is the most common and the least defensible idea in this space. Accelerating past what the label describes, combining amounts, or extending a prescription to cover more weeks are all regimen changes, and every one of them belongs to the prescriber who wrote it. The label states the reason for gradual escalation directly: to reduce the risk of gastrointestinal adverse reactions — the most frequent cause of people abandoning treatment entirely.

Severely restricting calories on top of the appetite suppression these medications produce is the second common error. Very low intake accelerates lean-tissue loss and raises the odds of nutritional gaps, and it works against the body-composition finding above. Adequate protein and resistance work exist to protect what you want to keep. What that looks like for you is a question for your clinician, not for an article.

Compounded Semaglutide Does Not Change This Calculus

Compounded semaglutide is not an FDA-approved finished product, and the FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed. It is not a generic version of Ozempic or Wegovy, since neither has an approved generic. It is prepared by a licensed pharmacy pursuant to a prescription for an individual patient.

None of the trial results cited above were produced with compounded material, so they describe the approved products rather than a compounded preparation. Whatever route you are on, the behavioral, dietary and activity findings still apply — those were tested as adjuncts, and adjunct is exactly how the approved labels describe the medication's role too.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Is Ozempic supposed to be used for weight loss?

No. Its label lists three indications, all in type 2 diabetes: improving glycemic control as an adjunct to diet and exercise, reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease, and reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with chronic kidney disease. Semaglutide is approved for weight management under a separate brand and label.

Why am I losing less weight than people I see online?

Diabetes status is a major factor. STEP 1 enrolled 1,961 adults without diabetes and reported a mean weight change of −14.9% at week 68 on semaglutide 2.4 mg. STEP 2 enrolled 1,210 adults with overweight or obesity and type 2 diabetes and reported −9.6% at the same timepoint. Same molecule, same duration, roughly a third less change. Other glucose-lowering medications can also influence weight.

Does adding structured behavioral support really change results?

The evidence says yes. STEP 3, published in JAMA, enrolled 611 adults for 68 weeks and gave intensive behavioral therapy plus an initial low-calorie diet to every participant. Estimated mean body weight change at week 68 was −16.0% with semaglutide versus −5.7% with placebo — the largest medication result across the STEP program, and a placebo result well above what unsupported placebo groups typically achieve.

Does exercise add anything if the medication is already working?

It changes what you lose. In a one-year randomized NEJM trial following an 8-week low-calorie diet, combining a moderate-to-vigorous exercise program with a GLP-1 medication cut body-fat percentage by 3.9 percentage points, roughly twice the reduction with exercise alone or medication alone. Only the combination improved glycated hemoglobin, insulin sensitivity, and cardiorespiratory fitness.

What happens to my weight if I stop treatment?

In the STEP 1 trial extension, 327 participants were followed for a year after both semaglutide 2.4 mg and the lifestyle intervention were withdrawn at week 68. Mean weight loss had been 17.3% at week 68; by week 120 participants had regained 11.6 percentage points, leaving a net 5.6% below baseline, with most cardiometabolic improvements reverting toward baseline. The authors concluded ongoing treatment is required to maintain improvements.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.